Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
This was originally designed as a phase I/II trial studying the side effects of sodium
stibogluconate and how well it works in treating patients with myelodysplastic syndromes.
Unfortunately, due to funding issues, the phase II portion was never conducted.